Apricus (APRI) Gains Korean Patent Approval for Nail Fungus Treatment MycoVa
Tweet
Share
E-mailGet Alerts APRI Hot Sheet
Join SI Premium – FREE
Apricus Biosciences, Inc. (Nasdaq: APRI) reports the Korean Patent Office will grant a patent for MycoVa, indicated for the treatment of onychomycosis (commonly referred to as nail fungus).
Specifically, the Korean Patent Office recently issued a "notice of allowance" for the Company's patent application, entitled, "Antifungal Nail Coat and Method of Use." Once issued, this will represent the fifth patent that Apricus Bio has received in Asia for MycoVa™ for onychomycosis, and the first in South Korea for this product. The patent will provide the Company with patent protection for MycoVa™ and its use for nail fungus in South Korea until March 2024.
Specifically, the Korean Patent Office recently issued a "notice of allowance" for the Company's patent application, entitled, "Antifungal Nail Coat and Method of Use." Once issued, this will represent the fifth patent that Apricus Bio has received in Asia for MycoVa™ for onychomycosis, and the first in South Korea for this product. The patent will provide the Company with patent protection for MycoVa™ and its use for nail fungus in South Korea until March 2024.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Real and RE/MAX Holdings receive court approval for merger
- Elroy Air wins $46M U.S. Army contract for cargo drone system
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
